EUCTR2015-005256-97-GB进行中（未招募）1 期
A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 300
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Adult subjects =18 years of age who are able to understand study procedures, comply with them, and provide written informed consent before any study-specific procedure.
- •2. History of cytologically or histologically confirmed diagnosis of AML (except acute promyelocytic leukemia) according to the 2008 World Health Organization (WHO) classification (bone marrow [BM] or peripheral blood [PB] blast counts =20%).
- •3. Performance status (Eastern Cooperative Oncology Group; ECOG) of 0-2.
- •4. Subjects with AML previously treated with induction therapy using an intensive chemotherapy regimen, defined as a regimen including cytarabine and an anthracycline, and who are refractory to induction (primary refractory) or in relapse after such induction with or without prior HCT.
- •5. Subjects must have either PB or BM blasts =5% at time of randomization.
- •6. Creatinine clearance or glomerular filtration rate =30 mL/min as estimated by the Cockroft-Gault (C-G) or other medically acceptable formulas, such as MDRD (Modification of Diet in Renal Disease) or CKD-EPI (the Chronic Kidney Disease Epidemiology Collaboration).
- •7. Women of child-bearing potential (according to recommendations of the Clinical Trial Facilitation Group [CTFG]; see below* for details) must not be pregnant or breastfeeding and must have a negative pregnancy test at screening. Women of child-bearing potential and men with female partners of child-bearing potential must agree to practice 2 highly effective contraceptive measures of birth control and must agree not to become pregnant or father a child (a) while receiving treatment with guadecitabine, decitabine, or azacitidine and for at
- •least 3 months after completing treatment and (b) while receiving treatment with highintensity TC or LDAC and for at least 6 months after completing treatment. Contraceptive measures which may be considered highly effective comprise combined hormonal contraception (oral, vaginal, or transdermal) or progestogen-only hormonal contraception(oral, injectable, implantable) associated with inhibition of ovulation, intrauterine device, intrauterine hormone-releasing system, bilateral tubal occlusion, sexual abstinence, and surgically successful vasectomy. Abstinence is acceptable only if it is consistent with the preferred and usual lifestyle of the subject. Periodic abstinence (eg, calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of birth control.
- •* According to recommendations of the CTFG (http://www.hma.eu/fileadmin/dateien/Human_Medicines/01-About_HMA/Working_Groups/CTFG/2014_09_HMA_CTFG_Contraception.pdf), a woman is considered of childbearing potential (ie, fertile) following menarche and until becoming postmenopausal, unless permanently sterile. Permanent sterilization methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy. A man is considered fertile after puberty unless permanently sterile by bilateral orchidectomy.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 150
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 150
排除标准
- •1. Known clinically active central nervous system (CNS) or extramedullary AML, except leukemia cutis.
- •2. Subjects who are in first relapse after initial induction, if they had a response duration of >12 months from date when first response was documented or if they are good candidates for HCT.
- •3. BCR-ABL-positive leukemia (chronic myelogenous leukemia in blast crisis).
- •4. Second malignancy currently requiring active therapy, except breast or prostate cancer stable on or responding to endocrine therapy.
- •5. Grade 3 or higher Graft Versus Host Disease (GVHD), or GVHD on either a calcineurin inhibitor or prednisone more than 5 mg/day. (Note: Prednisone at any dose for other indications is allowed.)
- •6. Prior treatment with guadecitabine for any indication, or more than 2 cycles of prior decitabine or azacitidine.
- •7. Hypersensitivity to decitabine, guadecitabine, or any of their excipients.
- •8. Treated with any investigational therapy within 2 weeks of the first dose of study treatment.
- •9. Total serum bilirubin >2.5 × upper limit of normal (ULN; except for subjects with Gilbert's Syndrome for whom direct bilirubin is <2.5 × ULN), or liver cirrhosis, or chronic liver disease Child-Pugh Class B or C.
- •10. Known active human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) infection. Inactive hepatitis carrier status or low viral hepatitis titer on antivirals is allowed.
- •11. Known significant mental illness or other condition such as active alcohol or other substance abuse or addiction that, in the opinion of the investigator, predisposes the subject to high risk of noncompliance with the protocol.
- •12. Refractory congestive heart failure unresponsive to medical treatment; active infection resistant to all antibiotics; or non-AMLassociated pulmonary disease requiring >2 liters per minute (LPM) oxygen or any other condition that puts the subject at an imminent risk of death.
- •13. Subjects with high PB blasts >50% AND poor ECOG PS of 2.
研究者
相似试验
进行中（未招募）
1 期
A Phase 3 Study to Compare Avelumab Given Alone or Given in Combination with Pegylated Liposomal Doxorubicin Compared to Pegylated Liposomal Doxorubicin Given Alone Patients with Platinum-Resistant/Refractory Ovarian CancerMedDRA version: 20.0 Level: PT Classification code 10033128 Term: Ovarian cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Ovarian CancerEUCTR2015-003091-77-ATPfizer Inc., 235 East 42nd Street, New York, NY 10017550
进行中（未招募）
1 期
A Phase 3 Study to Compare Avelumab Given Alone or Given in Combination with Pegylated Liposomal Doxorubicin Compared to Pegylated Liposomal Doxorubicin Given Alone Patients with Platinum-Resistant/Refractory Ovarian CancerOvarian CancerMedDRA version: 20.0 Level: PT Classification code 10033128 Term: Ovarian cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2015-003091-77-PLPfizer Inc., 235 East 42nd Street, New York, NY 10017550
进行中（未招募）
1 期
A clinical trial to compare guadecitabine (SGI-110) to other available therapies in patients with myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML) who have previously been treated with hypomethylating agentsMyelodysplastic syndromes (MDS)Chronic myelomonocytic leukemia (CMML)MedDRA version: 20.0Level: HLTClassification code 10028536Term: Myelodysplastic syndromesSystem Organ Class: 100000004851MedDRA version: 21.0Level: PTClassification code 10009018Term: Chronic myelomonocytic leukaemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2015-005257-12-BEAstex Pharmaceuticals, Inc.408
进行中（未招募）
1 期
A clinical trial to compare guadecitabine (SGI-110) to other available therapies in patients with myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML) who have previously been treated with hypomethylating agentsEUCTR2015-005257-12-DKAstex Pharmaceuticals, Inc.408
进行中（未招募）
1 期
A clinical trial to assess and compare overall survival (OS) between guadecitabine and treatment choice (TC) in adults with previously treated acute myeloid leukemia (AML)EUCTR2015-005256-97-SEAstex Pharmaceuticals, Inc.300